Type 2 diabetes may be an indication of pancreatic cancer

Washington D.C. [USA] Jun 19(ANI): Turns out, a recent-onset type 2 diabetes may be early expression of pancreatic cancer.

A new study published by Oxford University Press indicated that the recent-onset diabetes was associated with a 2.3-fold greater increase in risk of pancreatic cancer than long-standing diabetes.

Pancreatic cancer is one of the most fatal cancers, with a five-year survival rate of only 8 percent because majority pancreatic cancer patients are diagnosed at a late stage.

Diabetes is linked to both a risk factor for and a consequence of pancreatic cancer. The prevalence of diabetes among pancreatic cancer patients is unusually high as compared to other cancers.

The majority of the diabetes patients with pancreatic cancer are diagnosed with diabetes less than three years before being diagnosed with cancer. Among the patients undergoing pancreaticoduodenectomies (the surgical operation often used to try to remove pancreatic tumors), almost half have no diabetes postoperatively.

The researchers examined the association between recent-onset diabetes and pancreatic cancer in a prospective study of African Americans and Latinos, two minority populations with high diabetes risk.

Diabetes was found to be associated with an approximately twofold increased risk of pancreatic cancer. Importantly, the researchers demonstrated that the association of recent-onset diabetes with pancreatic cancer incidence was evident in African- Americans and Latinos.

The findings support the hypothesis that recent-onset diabetes in pancreatic cancer is a manifestation of developing pancreatic cancer.

“This striking relationship between recent-onset diabetes is unique to pancreatic cancer, and is not seen in breast, prostate and colorectal cancer in the cohort,” said one of the paper’s authors, Wendy Setiawan.

The study is published in Journal of the National Cancer Institute. (ANI)

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices